Close Menu

NEW YORK (GenomeWeb) – Trovagene announced today that it has signed an agreement to offer its circulating tumor DNA Precision Cancer Monitoring tests and services through America's Choice Provider Network (ACPN).

Under the terms of the deal, Trovagene has become a preferred provider for the network and its liquid biopsy testing services will be covered by more than 1,700 payors in North America and available under in-network coverage to 22 million individuals.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.